<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0004027'>Trisomy</z:mp> 11 (+11) as an isolated abnormality is a rare event in patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and is associated with poor prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>We describe the clinicopathologic features of 18 AML patients with isolated +11 and their mutation status of NPM1, FLT3, NRAS ,KRAS, and KIT </plain></SENT>
<SENT sid="2" pm="."><plain>Fourteen patients had de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 4 patients had a history of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Fifteen patients had a progressive clinical course with refractory or <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">relapsed disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The median overall survival was 5 months (range, 2 to 48 months) </plain></SENT>
<SENT sid="5" pm="."><plain>Only 1 patient achieved complete remission after undergoing stem cell transplantation </plain></SENT>
<SENT sid="6" pm="."><plain>The bone marrow median blast count was 65% (range, 22 to 86) and 14 patients had blasts &gt;50% </plain></SENT>
<SENT sid="7" pm="."><plain>The most common type of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> without maturation (7 patients) classified by the World Health Organization classification system, or M1 (10 patients) by the French-American-British (FAB) system </plain></SENT>
<SENT sid="8" pm="."><plain>FLT3 mutations were detected in 3 of 15 (20%) cases tested </plain></SENT>
<SENT sid="9" pm="."><plain><z:mp ids='MP_0011356'>RAS</z:mp> mutation was present in 1 of 16 (6%) cases and there was no evidence of NPM1 of KIT mutations (each tested in 12 cases) </plain></SENT>
<SENT sid="10" pm="."><plain>Our findings confirm previous reports that isolated +11 is associated with a poor prognosis in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and tends to be associated with <z:e sem="disease" ids="C0026998" disease_type="Neoplastic Process" abbrv="">FAB-M1</z:e> morphologic features </plain></SENT>
<SENT sid="11" pm="."><plain>No evidence of NPM1 or KIT mutations were identified </plain></SENT>
</text></document>